NAMS

NewAmsterdam is a single-asset, clinical-stage cardiometabolic company whose entire equity value rests on obicetrapib, an oral CETP inhibitor for LDL-C lowering. The MD&A confirms the program has cleared meaningful de-risking events: BROADWAY and BROOKLYN (obicetrapib monotherapy on top of statins) and TANDEM (obicetrapib + ezetimibe FDC) each met primary and secondary endpoints with statistically significant LDL-C reductions, and BROADWAY showed an exploratory 21% MACE reduction that the ongoing Phase 3 PREVAIL CVOT is designed to reconfirm. The EMA accepted the file for review in August 2025, and Menarini holds ex-US commercialization rights — a real partner validating the asset. That is why the market caps NAMS at $3.75B against just $22.5M of FY2025 revenue (P/S 166.7x): the price is not about the income statement, it is a probability-weighted bet on approval and uptake into a 30M-patient under-treated US ASCVD population that prefers oral over injectable therapy.

The numbers tell the other half of the story. FY2025 revenue fell 50.6% YoY to $22.5M (lumpy partnership/license income, not product sales), net loss was $204M, operating loss $226M, and accumulated deficit reached $762M. Operating cash burn was $148M against $490M cash on hand — roughly three years of runway at current burn, but R&D ($142M) will likely step up through PREVAIL and any pre-launch build, and the share count is already creeping (115M, +4.7% YoY), foreshadowing more dilution. The balance sheet is clean (liabilities/equity 0.13x, no debt stress), which is the right shape for a clinical-stage biotech, but ROE of -29.8% and operating margin of -1003% are not investment signals — they simply mark this as a binary asset.